Fluorescent near-infrared imaging can accurately detect pancreatic cancer non-invasively during a whipple procedure.
ID
Bron
Verkorte titel
Aandoening
Pancreatic cancer
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Primary outcome parameter is the number of identified pancreatic tumors.
Achtergrond van het onderzoek
Pancreatic cancer is the third leading cause of cancer-related death in the United States and Europe. Surgical resection is the only available curative therapy. During pancreatic surgery, it is often hard to differentiate between malignant tissue and benign tissue. In over 35% of cases, the resection margins appear to be positive. To reduce the numer of patients with positive resection margins, near-infrared fluorescence imaging can be very usefull.
Standard Whipple procedure will be performed. During surgery, the near-infrared dye MB will be injected and the pancreatic carcinoma will be visualized non-invasively using our experimental camerasystem.
Doel van het onderzoek
Fluorescent near-infrared imaging can accurately detect pancreatic cancer non-invasively during a whipple procedure.
Onderzoeksopzet
The primary and secondary outcomes will be assessed during surgery and pathological assessment.
Onderzoeksproduct en/of interventie
Standard Whipple procedure will be performed. During surgery, the near-infrared dye Methylene blue (MB) will be injected and the pancreatic carcinoma will be visualized non-invasively using our experimental camerasystem.
Publiek
Department of Surgical Oncology,
P.O. Box 9600
C.J.H. Velde, van de
Leiden 2300 RC
The Netherlands
+31 (0)71 5262309
c.j.h.van_de_velde@lumc.nl
Wetenschappelijk
Department of Surgical Oncology,
P.O. Box 9600
C.J.H. Velde, van de
Leiden 2300 RC
The Netherlands
+31 (0)71 5262309
c.j.h.van_de_velde@lumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Patients diagnosed with pancreatic cancer eligible to undergo a curative resection;
2. Age between 18 and 80 years old.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Patients using SSRI's, SNRI's of TCA's;
2. Allergy to methyleen blue, history of severe renal impairment or G6PD-deficiency;
3. Patient pregnant or lactating.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL3318 |
| NTR-old | NTR3465 |
| Ander register | METC LUMC : P10.001 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |